scholarly article | Q13442814 |
P50 | author | Leon J. Thal | Q56839882 |
Cora E Lewis | Q87075032 | ||
Lewis Kuller | Q88077314 | ||
Marcia L. Stefanick | Q109542605 | ||
Kamal H Masaki | Q114312000 | ||
Sally A Shumaker | Q114424439 | ||
Stephen R. Rapp | Q124352318 | ||
Laura H. Coker | Q124354721 | ||
P2093 | author name string | Susan L Hendrix | |
Claudine Legault | |||
Dorothy S Lane | |||
Howard Fillit | |||
Women's Health Initiative Memory Study | |||
P433 | issue | 24 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | mild cognitive impairment | Q1472703 |
estrogen | Q277954 | ||
cognitive dysfunction | Q57859955 | ||
dementia | Q83030 | ||
P304 | page(s) | 2947-2958 | |
P577 | publication date | 2004-06-01 | |
P1433 | published in | The Journal of the American Medical Association | Q1470970 |
P1476 | title | Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study | |
P478 | volume | 291 |
Q34220854 | "I Am Hot, Irritable and Feeling Low; What Alternatives do I have Besides Hormone Replacement Therapy?". |
Q33825736 | 17α-estradiol attenuates neuron loss in ovariectomized Dtg AβPP/PS1 mice. |
Q56031121 | 17α-estradiol: a less-feminizing estrogen |
Q57157080 | A Heartfelt Message, Estrogen Replacement Therapy: Use It or Lose It |
Q37547427 | A cell-biased effect of estrogen in prion infection. |
Q38846232 | A comparison of progestins within three classes: Differential effects on learning and memory in the aging surgically menopausal rat. |
Q34316221 | A component of Premarin® enhances multiple cognitive functions and influences nicotinic receptor expression |
Q33745024 | A cross-sectional study of hormone treatment and hippocampal volume in postmenopausal women: evidence for a limited window of opportunity |
Q46794182 | A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss |
Q35986045 | A lack of ovarian function increases neuroinflammation in aged mice |
Q38316448 | A major role for cardiovascular burden in age-related cognitive decline |
Q33925274 | A new approach to understanding the molecular mechanisms through which estrogens affect cognition |
Q36797166 | A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial |
Q30491831 | A theory of eu-estrogenemia: a unifying concept |
Q90263988 | Accelerated Ovarian Failure as a Unique Model to Study Peri-Menopause Influence on Alzheimer's Disease |
Q36990320 | Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia |
Q35322167 | Advances in the prevention of Alzheimer's disease and dementia |
Q55395274 | Age at menopause and lifetime cognition: Findings from a British birth cohort study. |
Q37623629 | Age-dependent Effects of 17β-estradiol on the dynamics of estrogen receptor β (ERβ) protein-protein interactions in the ventral hippocampus |
Q36511909 | Age-related changes in neuroprotection: is estrogen pro-inflammatory for the reproductive senescent brain? |
Q36721813 | Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease |
Q36164324 | Aging and Loss of Circulating 17β-Estradiol Alters the Alternative Splicing of ERβ in the Female Rat Brain |
Q36795162 | Aging and substitutive hormonal therapy influence in regional and subcellular distribution of ERα in female rat brain |
Q36633134 | Aging of brain: role of estrogen. |
Q37470780 | Aging, estrogens, and episodic memory in women |
Q34593121 | Allopregnanolone impairs episodic memory in healthy women |
Q58452030 | Alzheimer's Disease |
Q37272133 | Alzheimer's Disease in Adults with Down Syndrome |
Q64163825 | Alzheimer's Disease: Progress in the Development of Anti-amyloid Disease-Modifying Therapies |
Q34039983 | Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments |
Q36026972 | Alzheimer's and dementia in the oldest-old: a century of challenges |
Q29616743 | Alzheimer's disease |
Q36894385 | Alzheimer's disease and mild cognitive impairment |
Q36946824 | Alzheimer's disease and other neurological disorders |
Q30620862 | Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'? |
Q57074482 | Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders |
Q38871979 | Alzheimer's disease, menopause and the impact of the estrogenic environment |
Q37315515 | Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause |
Q33773031 | Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible |
Q35987458 | Ambient air pollution and neurotoxicity on brain structure: Evidence from women's health initiative memory study |
Q46129248 | An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials |
Q34719941 | An update on hormone replacement therapy: health and medicine for women: a multidisciplinary, evidence-based review of mid-life health concerns. |
Q37084906 | An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms |
Q33896147 | An update on the diagnosis and management of dementing conditions |
Q37576090 | An update on treatment and prevention strategies for Alzheimer's disease |
Q31029649 | Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761. |
Q34810472 | Application of machine learning methods to describe the effects of conjugated equine estrogens therapy on region-specific brain volumes |
Q35237981 | Ascertaining dementia-related outcomes for deceased or proxy-dependent participants: an overview of the Women's Health Initiative Memory Study supplemental case ascertainment protocol |
Q37015181 | Assessment of estradiol influence on spatial tasks and hippocampal CA1 spines: evidence that the duration of hormone deprivation after ovariectomy compromises 17beta-estradiol effectiveness in altering CA1 spines |
Q38392550 | Association of bilateral oophorectomy with cognitive function in healthy, postmenopausal women |
Q38129325 | Atypical aging in Down syndrome |
Q50783742 | Benchmarks for designing two-stage studies using modified mini-mental state examinations: experience from the Women's Health Initiative Memory Study. |
Q37483121 | Benefits of Hormone Therapy Estrogens Depend on Estrogen Type: 17β-Estradiol and Conjugated Equine Estrogens Have Differential Effects on Cognitive, Anxiety-Like, and Depressive-Like Behaviors and Increase Tryptophan Hydroxylase-2 mRNA Levels in Dor |
Q35072737 | Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a novel GPR30-dependent Mechanism |
Q24643351 | Bioidentical hormones for menopausal hormone therapy: variation on a theme |
Q91984204 | Blood pressure variability and brain morphology in elderly women without cardiovascular disease |
Q34708973 | Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review |
Q36650676 | Brain endogenous estrogen levels determine responses to estrogen replacement therapy via regulation of BACE1 and NEP in female Alzheimer's transgenic mice |
Q34091893 | Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease |
Q37413116 | Brain volumes, cognitive impairment, and conjugated equine estrogens |
Q36349176 | Brain-derived neurotrophic factor Val(66)Met genotype and ovarian steroids interactively modulate working memory-related hippocampal function in women: a multimodal neuroimaging study |
Q36106017 | Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for age-related memory decline. |
Q36843004 | CAP--advancing the evaluation of preclinical Alzheimer disease treatments |
Q91825612 | CB1 agonism prolongs therapeutic window for hormone replacement in ovariectomized mice |
Q36463375 | Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative |
Q36130681 | Can endocrine disruptors influence neuroplasticity in the aging brain? |
Q35625177 | Cancer and Dementia: It's Complicated |
Q37688153 | Cardiovascular disease is preventable among women |
Q36892860 | Care of the menopausal patient: a nurse practitioner's view |
Q34361818 | Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. |
Q99573908 | Characterizing the effects of tonic 17β-estradiol administration on spatial learning and memory in the follicle-deplete middle-aged female rat |
Q34978792 | Chronic treatment with the nitric oxide synthase inhibitor, L-NAME, attenuates estradiol-mediated improvement of learning and memory in ovariectomized rats |
Q37477478 | Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. |
Q31155412 | Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology |
Q36632771 | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology |
Q37810697 | Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology |
Q37088621 | Cognitive changes after menopause: influence of estrogen |
Q36919235 | Cognitive decline and dementia in the oldest-old |
Q45960420 | Cognitive effects of short-term use of raloxifene: a randomized clinical trial. |
Q36539736 | Cognitive performance in healthy women during induced hypogonadism and ovarian steroid addback |
Q92656269 | Cognitive resilience among APOE ε4 carriers in the oldest old |
Q48305628 | Cognitive symptoms during the menopausal transition and early postmenopause |
Q37207741 | Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across time |
Q37352376 | Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges |
Q24186056 | Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates |
Q37650744 | Complexities of oestrogen in stroke |
Q36948674 | Conjugated equine estrogen enhances rats' cognitive, anxiety, and social behavior |
Q30659580 | Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data |
Q47568706 | Consensus Approaches to Identify Incident Dementia in Cohort Studies: Systematic Review and Approach in the Successful Aging after Elective Surgery Study |
Q33600226 | Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years |
Q33874451 | Continuous and cyclic progesterone differentially interact with estradiol in the regulation of Alzheimer-like pathology in female 3xTransgenic-Alzheimer's disease mice |
Q36095863 | Continuous estrone treatment impairs spatial memory and does not impact number of basal forebrain cholinergic neurons in the surgically menopausal middle-aged rat |
Q34185639 | Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles |
Q37642394 | Continuously delivered ovarian steroids do not alter dendritic spine density or morphology in macaque dorsolateral prefrontal cortical neurons |
Q30634935 | Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies |
Q34067487 | Current treatment and recent clinical research in Alzheimer's disease |
Q36575001 | Current treatment of mild cognitive impairment and Alzheimer's disease |
Q38778638 | Defeating Alzheimer's disease and other dementias: a priority for European science and society |
Q33924014 | Dementia and cognitive impairment: epidemiology, diagnosis, and treatment |
Q64109996 | Dementia outcomes after addition of proxy-based assessments for deceased or proxy-dependent participants |
Q37263684 | Dementia prevention: methodological explanations for inconsistent results |
Q36787352 | Dementia syndromes: evaluation and treatment |
Q35994372 | Dementia: finding the signals in the noise |
Q33915401 | Demographic and health factors associated with enrollment in posttrial studies: the Women's Health Initiative Hormone Therapy Trials |
Q48930833 | Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study |
Q39657169 | Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study |
Q35028141 | Depressive symptoms, brain volumes and subclinical cerebrovascular disease in postmenopausal women: the Women's Health Initiative MRI Study |
Q34216817 | Development of subtype-selective oestrogen receptor-based therapeutics. |
Q24646877 | Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease |
Q43196397 | Diet and the risk for Alzheimer's disease |
Q35005274 | Dietary inflammation factor rating system and risk of Alzheimer disease in elders. |
Q45841349 | Differences Between Gynecologists and Primary Care Physicians in Hormone Therapy Prescribing: Why They Matter |
Q34494238 | Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. |
Q36818199 | Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women |
Q37143947 | Differential effects on visual and spatial recognition memory of a novel hormone therapy regimen of estrogen alone or combined with progesterone in older surgically menopausal monkeys |
Q35029513 | Do aromatase inhibitors have adverse effects on cognitive function? |
Q37332321 | Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis |
Q37157784 | Dose-dependent effects of post-training estradiol plus progesterone treatment on object memory consolidation and hippocampal extracellular signal-regulated kinase activation in young ovariectomized mice |
Q36826910 | Driving with Mild Cognitive Impairment or Dementia: Cognitive Test Performance and Proxy Report of Daily Life Function in Older Women |
Q34320568 | Duration of estrogen deprivation, not chronological age, prevents estrogen's ability to enhance hippocampal synaptic physiology |
Q51037908 | EFNS guidelines for the diagnosis and management of Alzheimer's disease. |
Q37113841 | Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition |
Q35498087 | Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity |
Q33981652 | Early menopausal hormone use influences brain regions used for visual working memory |
Q37460286 | Early, but not late onset estrogen replacement therapy prevents oxidative stress and metabolic alterations caused by ovariectomy. |
Q28071845 | Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer's Disease |
Q46459550 | Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. |
Q28384228 | Effect of dietary legumes on bone-specific gene expression in ovariectomized rats |
Q36684570 | Effects of Hormone Therapy on Brain Volumes Changes of Postmenopausal Women Revealed by Optimally-Discriminative Voxel-Based Morphometry |
Q51144893 | Effects of chronic oestradiol, progesterone and medroxyprogesterone acetate on hippocampal neurogenesis and adrenal mass in adult female rats. |
Q37417437 | Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy |
Q46528069 | Effects of estrogen and estrogenic compounds on cognition in ovariectomized rats |
Q46731148 | Effects of estrogen and progestin on hypothalamic blood flow autoregulation |
Q33552696 | Effects of hormone replacement therapy on magnetic resonance imaging of brain parenchyma hyperintensities in postmenopausal women |
Q26865143 | Effects of hormone therapy on cognition and mood |
Q33889042 | Effects of long-term treatment with 17 beta-estradiol and medroxyprogesterone acetate on water maze performance in middle aged female rats |
Q48100705 | Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. |
Q41442478 | Effects of synaptic plasticity regulated by 17beta-estradiol on learning and memory in rats with Alzheimer's disease |
Q37439245 | Effects of two years of conjugated equine estrogens on cholinergic neurons in young and middle-aged ovariectomized monkeys |
Q34959106 | Endocrine disruptors as a threat to neurological function |
Q37141534 | Endpoints for trials in Alzheimer's disease: a European task force consensus |
Q35915312 | Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). |
Q36546512 | Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease |
Q37947688 | Epidemiological findings of vascular risk factors in Alzheimer's disease: implications for therapeutic and preventive intervention |
Q34991223 | Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention |
Q40069328 | Epidemiology of estrogen and dementia in women with Down syndrome |
Q57781941 | Epidemiology of neurological diseases in elderly people: what did we learn from the Rotterdam Study? |
Q38708380 | Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). |
Q37085132 | Estradiol and neurodegenerative oxidative stress |
Q37484251 | Estradiol and the relationship between dendritic spines, NR2B containing NMDA receptors, and the magnitude of long-term potentiation at hippocampal CA3-CA1 synapses |
Q48330937 | Estradiol enhances neurogenesis following ischemic stroke through estrogen receptors alpha and beta |
Q36732302 | Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis |
Q36713849 | Estradiol or diarylpropionitrile administration to wild type, but not estrogen receptor beta knockout, mice enhances performance in the object recognition and object placement tasks |
Q36745218 | Estradiol reduces anxiety- and depression-like behavior of aged female mice |
Q33875866 | Estradiol replacement extends the window of opportunity for hippocampal function |
Q33779918 | Estradiol-induced object memory consolidation in middle-aged female mice requires dorsal hippocampal extracellular signal-regulated kinase and phosphatidylinositol 3-kinase activation |
Q33558982 | Estrogen Secreted by Mesenchymal Stem Cells Necessarily Determines Their Feasibility of Therapeutical Application. |
Q30478476 | Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines |
Q92345807 | Estrogen activates Alzheimer's disease genes |
Q50891302 | Estrogen administration negatively alters mood following monoaminergic depletion and psychosocial stress in postmenopausal women. |
Q42491540 | Estrogen alters spine number and morphology in prefrontal cortex of aged female rhesus monkeys. |
Q37076464 | Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial |
Q36039975 | Estrogen and memory in women: how can we reconcile the findings? |
Q24658109 | Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society |
Q34784469 | Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases |
Q33591732 | Estrogen deficiency is associated with hippocampal morphological remodeling of early postmenopausal mice |
Q42436195 | Estrogen effects on high-affinity choline uptake in primary cultures of rat basal forebrain |
Q33929847 | Estrogen intake and copper depositions: implications for Alzheimer's disease? |
Q30480285 | Estrogen modifies arousal but not memory for emotional events in older women |
Q48488958 | Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females |
Q90222498 | Estrogen receptor α promotes Cav1.2 ubiquitination and degradation in neuronal cells and in APP/PS1 mice |
Q36322578 | Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics |
Q34360055 | Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease |
Q37675866 | Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease |
Q51001119 | Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: a randomized trial. |
Q46058009 | Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment |
Q21284766 | Estrogen signaling and the aging brain: context-dependent considerations for postmenopausal hormone therapy |
Q92042117 | Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases |
Q36677805 | Estrogen synthesis and signaling pathways during aging: from periphery to brain |
Q46233165 | Estrogen therapy affects right hemisphere functioning in postmenopausal women |
Q48335998 | Estrogen therapy and brain muscarinic receptor density in healthy females: a SPET study |
Q33779694 | Estrogen therapy and cognition: a review of the cholinergic hypothesis |
Q37618547 | Estrogen therapy: is time of initiation critical for neuroprotection? |
Q46947447 | Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women |
Q34144464 | Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women |
Q99345086 | Estrogen, brain structure, and cognition in postmenopausal women |
Q34585797 | Estrogen, cognition and female ageing |
Q36621171 | Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. |
Q33623924 | Estrogen: a master regulator of bioenergetic systems in the brain and body |
Q34583150 | Estrogen: effects on normal brain function and neuropsychiatric disorders. |
Q28079898 | Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases |
Q80815527 | Estrogens and Stroke: Use of Oral Contraceptives and Postmenopausal Use of Estrogen: Current Recommendations |
Q37147787 | Estrogens and age-related memory decline in rodents: what have we learned and where do we go from here? |
Q36980880 | Estrogens and progesterone as neuroprotectants: what animal models teach us |
Q38739583 | Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury |
Q36931711 | Estrogens, episodic memory, and Alzheimer's disease: a critical update |
Q34269755 | Estrogens, estrogen receptors, and female cognitive aging: the impact of timing |
Q35193759 | Evidence regarding the benefits of physical exercise |
Q50600187 | Executive functions in men and postmenopausal women. |
Q49586649 | FSH to estradiol ratio can be used as screening method for mild cognitive impairment in postmenopausal women |
Q36901959 | Factors influencing the cognitive and neural effects of hormone treatment during aging in a rodent model |
Q37090625 | Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement |
Q56673117 | Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive |
Q35034379 | Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative Memory Study. |
Q37324566 | Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study". |
Q35816802 | Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia |
Q92543481 | GABA-A receptor modulating steroids in acute and chronic stress; relevance for cognition and dementia? |
Q33565734 | GC-TOF/MS-based metabolomic profiling of estrogen deficiency-induced obesity in ovariectomized rats |
Q34612871 | GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance |
Q35534146 | Galanthamine plus estradiol treatment enhances cognitive performance in aged ovariectomized rats |
Q92542344 | Gender Difference in the Effects of Outdoor Air Pollution on Cognitive Function Among Elderly in Korea |
Q38225583 | Gender and cataract--the role of estrogen |
Q41717521 | Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients |
Q36089835 | Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels |
Q42363857 | Genetic Analysis of Mitochondrial Ribosomal Proteins and Cognitive Aging in Postmenopausal Women |
Q37795699 | Genetic variability in estrogen disposition: Potential clinical implications for neuropsychiatric disorders |
Q36227902 | Geographic Elevation and Cognitive Function among Elderly Residents in Rural Mountainous Areas: Shimane CoHRE Study |
Q37028001 | Global cognitive function before, surrounding, and after ischemic stroke: the role of risk and protective factors varies with time among ischemic stroke survivors |
Q36909207 | Gonadal hormones and cognitive aging: a midlife perspective |
Q36914297 | Guarding the blood-brain barrier: a role for estrogen in the etiology of neurodegenerative disease. |
Q53597256 | Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. |
Q22306361 | Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association |
Q36755714 | Higher levels of estradiol replacement correlate with better spatial memory in surgically menopausal young and middle-aged rats |
Q52147336 | Hippocampal Lipid Homeostasis in APP/PS1 Mice is Modulated by a Complex Interplay Between Dietary DHA and Estrogens: Relevance for Alzheimer's Disease. |
Q34680911 | Hormonal influences on cognition and risk for Alzheimer's disease |
Q37029421 | Hormonal treatment, mild cognitive impairment and Alzheimer's disease |
Q24242542 | Hormone replacement therapy for cognitive function in postmenopausal women |
Q36668526 | Hormone replacement therapy in menopausal women: Past problems and future possibilities |
Q24241789 | Hormone replacement therapy to maintain cognitive function in women with dementia |
Q36240364 | Hormone replacement therapy: an update |
Q36475295 | Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. |
Q37381044 | Hormone therapy and cognitive function |
Q36887336 | Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. |
Q38975101 | Hormone-replacement therapy: current thinking |
Q36362593 | Hormones and menopause: pro. |
Q35876440 | Hypertension and dementia: does blood pressure control favorably affect cognition? |
Q36492399 | Hypertension, Dietary Sodium, and Cognitive Decline: Results From the Women's Health Initiative Memory Study |
Q34626471 | IMS updated recommendations on postmenopausal hormone therapy |
Q36311674 | Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women |
Q37764494 | Impact of the hypothalamic-pituitary-adrenal/gonadal axes on trajectory of age-related cognitive decline |
Q36976420 | In vivo profiling of estrogen receptor/specificity protein-dependent transactivation |
Q34316296 | Increased memory load-related frontal activation after estradiol treatment in postmenopausal women |
Q24645015 | Increased mortality for neurological and mental diseases following early bilateral oophorectomy |
Q28584559 | Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis |
Q36268931 | Influences of hormone replacement therapy on olfactory and cognitive function in postmenopausal women |
Q26863428 | Insights into rapid modulation of neuroplasticity by brain estrogens |
Q28394967 | Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors |
Q35958716 | Interviews With Two Women's Health Experts On the Use of Estrogen Therapies. |
Q37436161 | Intraindividual variability in domain-specific cognition and risk of mild cognitive impairment and dementia |
Q37018510 | Is timing everything? New insights into why the effect of estrogen therapy on memory might be age dependent |
Q36970351 | Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. |
Q38831286 | L-Type Calcium Channels Modulation by Estradiol |
Q33854590 | Lack of association of acute phase response proteins with hormone levels and antidepressant medication in perimenopausal depression |
Q36176198 | Life-long environmental enrichment differentially affects the mnemonic response to estrogen in young, middle-aged, and aged female mice. |
Q24647962 | Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist |
Q24201974 | Long term hormone therapy for perimenopausal and postmenopausal women |
Q24241279 | Long term hormone therapy for perimenopausal and postmenopausal women |
Q24246577 | Long term hormone therapy for perimenopausal and postmenopausal women |
Q35616166 | Long-term consequences of estrogens administered in midlife on female cognitive aging |
Q37277562 | Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging |
Q34048789 | Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension |
Q37352051 | Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years |
Q51974359 | Long-term estrogen therapy and 5-HT(2A) receptor binding in postmenopausal women; a single photon emission tomography (SPET) study. |
Q36089352 | Long-term health consequences of premature or early menopause and considerations for management |
Q30238978 | Long-term hormone therapy for perimenopausal and postmenopausal women |
Q35718091 | Long-term replacement of estrogen in combination with medroxyprogesterone acetate improves acquisition of an alternation task in middle-aged female rats |
Q41102759 | Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study |
Q36456541 | Longer duration of hormonal contraceptive use predicts better cognitive outcomes later in life |
Q37001444 | Longitudinal study of low serum LDL cholesterol and depressive symptom onset in postmenopause |
Q33591187 | Lost in translation: epidemiology, risk, and Alzheimer disease |
Q92648681 | Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial |
Q57492371 | Luteinizing Hormone Involvement in Aging Female Cognition: Not All Is Estrogen Loss |
Q58485914 | Maintaining cognitive health in elderly women |
Q35742248 | Managing the menopause. |
Q37322698 | Manipulation of Ovarian Function Significantly Influenced Sarcopenia in Postreproductive-Age Mice |
Q35882023 | Manipulation of Ovarian Function Significantly Influenced Trabecular and Cortical Bone Volume, Architecture and Density in Mice at Death |
Q37245953 | Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens |
Q37048086 | Medical management of frontotemporal dementia |
Q22242806 | Medications and Diet |
Q92132021 | Medroxyprogesterone Acetate Impairs Amyloid Beta Degradation in a Matrix Metalloproteinase-9 Dependent Manner |
Q35168390 | Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function |
Q30465714 | Medroxyprogesterone acetate impairs memory and alters the GABAergic system in aged surgically menopausal rats. |
Q40045531 | Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials |
Q37349131 | Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends |
Q36152764 | Menopausal hormone therapy |
Q37658616 | Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials |
Q37822795 | Menopause and mental well-being: timing of symptoms and timing of hormone treatment |
Q43028519 | Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy |
Q34356193 | Menopause effects on verbal memory: findings from a longitudinal community cohort |
Q21131065 | Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease |
Q37030684 | Menopause: developing a rational treatment plan |
Q34347589 | MicroRNAs in the aging female brain: a putative mechanism for age-specific estrogen effects. |
Q26994975 | Mild cognitive impairment and dementia: the importance of modifiable risk factors |
Q34572010 | Mild cognitive impairment: The dilemma. |
Q36113990 | Minireview: translational animal models of human menopause: challenges and emerging opportunities |
Q28392016 | Modeling menopause: The utility of rodents in translational behavioral endocrinology research |
Q38243574 | Molecular signature of rapid estrogen regulation of synaptic connectivity and cognition |
Q31122463 | Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board |
Q36611546 | Mortality in women given diethylstilbestrol during pregnancy. |
Q36756290 | Multiple clinically relevant hormone therapy regimens fail to improve cognitive function in aged ovariectomized rhesus monkeys |
Q51692831 | Neighborhood socioeconomic status and cognitive function in women. |
Q24630024 | Neurobiological Underpinnings of the Estrogen - Mood Relationship |
Q64460778 | Neuroimmunology of the female brain across the lifespan: Plasticity to psychopathology |
Q57823065 | Neurological health and premature ovarian insufficiency - pathogenesis and clinical management |
Q38005895 | Neuroprotection and estrogen receptors |
Q37479919 | Neuroprotective actions of selective estrogen receptor modulators. |
Q41100832 | Neuroprotective and Memory-Enhancing Effect of the Combined Extract of Purple Waxy Corn Cob and Pandan in Ovariectomized Rats. |
Q33762953 | Neuroprotective effects of estrogen therapy for cognitive and neurobiological profiles of monkey models of menopause |
Q35078498 | Neuroscientists as cartographers: mapping the crossroads of gonadal hormones, memory and age using animal models |
Q35779578 | Neurosteroid effects at α4βδ GABAA receptors alter spatial learning and synaptic plasticity in CA1 hippocampus across the estrous cycle of the mouse |
Q35971833 | Neurosteroids and GABA-A Receptor Function |
Q46407690 | New thoughts about estrogen therapy from the Women's Health Initiative |
Q31070019 | No Association between Dietary Patterns and Risk for Cognitive Decline in Older Women with 9-Year Follow-Up: Data from the Women's Health Initiative Memory Study |
Q50935037 | No differences in performance on test of working memory and executive functioning between healthy elderly postmenopausal women using or not using hormone therapy. |
Q36459049 | Novel mechanisms for estrogen-induced neuroprotection |
Q37283496 | Number of children is associated with neuropathology of Alzheimer's disease in women |
Q46828775 | Oestrogen doesn't protect mental function in older women |
Q46799979 | Oestrogen receptor α agonist improved long-term ovariectomy-induced spatial cognition deficit in young rats |
Q36690367 | Oestrogen, cognition and the maturing female brain. |
Q33677382 | Omega-3 fatty acids and cognitive function in women |
Q26853730 | Oophorectomy, estrogen, and dementia: a 2014 update |
Q34612492 | Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity |
Q33808780 | Oophorectomy, menopause, estrogen, and cognitive aging: the timing hypothesis |
Q60954733 | Ovarian Cycle Stages Modulate Alzheimer-Related Cognitive and Brain Network Alterations in Female Mice |
Q37633232 | Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models |
Q34478669 | Pharmacological strategies for the prevention of Alzheimer's disease |
Q37004359 | Pharmacotherapy of Alzheimer disease |
Q47582925 | Polymorphisms of the estrogen receptor alpha (ESR1) gene and the risk of Alzheimer's disease in a southern Chinese community |
Q43154107 | Post hoc magnetic resonance imaging cannot justify the conclusions of WHIMS. |
Q42840295 | Postmenopausal hormone therapy |
Q37742148 | Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study |
Q27008086 | Postmenopausal hormone therapy and cognition |
Q51861170 | Postmenopausal hormone therapy and cognition: effects of timing and treatment type. |
Q33516441 | Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). |
Q37180441 | Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study |
Q37180460 | Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study |
Q34420014 | Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke |
Q37416371 | Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease |
Q36355137 | Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline |
Q36156641 | Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes |
Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
Q38082563 | Postmenopausal hormone therapy: risks and benefits |
Q89562164 | Postmenopausal hormone treatment alters neural pathways but does not improve verbal cognitive function |
Q36661099 | Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia |
Q46664316 | Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond--a commentary based on clinical experience |
Q37418919 | Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease. |
Q34312062 | Predicting Alzheimer's disease in the Baltimore longitudinal study of aging |
Q40283154 | Preeclampsia and cognitive impairment later in life |
Q36296643 | Preliminary evidence that long-term estrogen use reduces white matter loss in aging |
Q37417828 | Premarin improves memory, prevents scopolamine-induced amnesia and increases number of basal forebrain choline acetyltransferase positive cells in middle-aged surgically menopausal rats |
Q33278956 | Premature ovarian failure: a review |
Q34847609 | Preventing Alzheimer's disease : separating fact from fiction |
Q37001410 | Preventing cognitive decline in healthy older adults |
Q38719665 | Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives |
Q34683795 | Prevention of Alzheimer disease. Encouraging evidence. |
Q22248031 | Prevention of Alzheimer's disease |
Q53499870 | Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. |
Q38554910 | Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions |
Q38983318 | Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics |
Q88615781 | Previous estradiol treatment in ovariectomized mice provides lasting enhancement of memory and brain estrogen receptor activity |
Q37670673 | Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward |
Q36806653 | Primary prevention and delay of onset of AD/dementia |
Q37072797 | Progesterone influence on neurite outgrowth involves microglia. |
Q37220808 | Progesterone reduces depression-like behavior in a murine model of Alzheimer's Disease |
Q36436653 | Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK. |
Q36545649 | Prolonged ovarian hormone deprivation alters the effects of 17β-estradiol on microRNA expression in the aged female rat hypothalamus |
Q33544151 | Promoting successful cognitive aging: a comprehensive review |
Q33851285 | Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles |
Q35119064 | Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia |
Q37309638 | Protective actions of sex steroid hormones in Alzheimer's disease |
Q36972735 | Protein phosphatase 1, protein phosphatase 2A, and calcineurin play a role in estrogen-mediated neuroprotection |
Q37261100 | Provider attributes associated with hormone therapy prescribing frequency |
Q34125853 | Psychiatric disorders and cognitive dysfunction among older, postmenopausal women: results from the Women's Health Initiative Memory Study |
Q90666336 | Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer |
Q35972436 | Rapid estradiol modulation of neuronal connectivity and its implications for disease |
Q37063691 | Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog) |
Q36380901 | Re-Opening the Critical Window for Estrogen Therapy |
Q36946779 | Recent epidemiological evidence relevant to the clinical management of the menopause |
Q38002365 | Recruitment methods for United States Alzheimer disease prevention trials |
Q33831158 | Relationship of hypertension, blood pressure, and blood pressure control with white matter abnormalities in the Women's Health Initiative Memory Study (WHIMS)-MRI trial |
Q33841626 | Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition |
Q49957773 | Reproductive endocrinology: Postmenopausal hormone therapy to prevent chronic conditions |
Q56031122 | Review of the effects of 17α-estradiol in humans: a less feminizing estrogen with neuroprotective potential |
Q37889475 | Risk profiles of Alzheimer disease |
Q24647700 | Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence |
Q46633788 | Role of protein phosphatases in estrogen-mediated neuroprotection. |
Q37014605 | Role of psychiatric comorbidity on cognitive function during and after the menopausal transition |
Q24625569 | Roles for oestrogen receptor β in adult brain function |
Q36794420 | SERMs for the treatment and prevention of breast cancer |
Q38700757 | Safety and benefit considerations for menopausal hormone therapy |
Q33236269 | Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disea |
Q40430713 | Serum lipid changes following the onset of depressive symptoms in postmenopausal women |
Q90250191 | Sex Differences in Cardiovascular Disease and Cognitive Impairment: Another Health Disparity for Women? |
Q38878236 | Sex Hormones and Cognition: Neuroendocrine Influences on Memory and Learning |
Q92023923 | Sex and Gender Differences in Alzheimer's Disease Dementia |
Q34214272 | Sex and gender differences in the causes of dementia: a narrative review |
Q36473640 | Sex and gonadal hormones in mouse models of Alzheimer's disease: what is relevant to the human condition? |
Q50506777 | Sex and post-menopause hormone therapy effects on hippocampal volume and verbal memory. |
Q37432182 | Sex and the development of Alzheimer's disease. |
Q33864547 | Sex differences in cognitive impairment and Alzheimer's disease |
Q82035418 | Sex differences in stroke |
Q49601287 | Sex-related differences in oxidative stress and neurodegeneration |
Q36758718 | Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause |
Q46342146 | Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study |
Q56505904 | Single-Sex Education and the Brain |
Q36373516 | Sleep duration, cognitive decline, and dementia risk in older women |
Q90074464 | Statin therapy: does sex matter? |
Q38242935 | Steroid hormones, receptors, and perceptual and cognitive sex differences in the visual system |
Q37714345 | Stroke in women |
Q34088579 | Subtypes of mild cognitive impairment in older postmenopausal women: the Women's Health Initiative Memory Study |
Q43424580 | Sugary foods and gynecological cancer risk |
Q35641917 | Suppression of beta-amyloid precursor protein signaling into the nucleus by estrogens mediated through complex formation between the estrogen receptor and Fe65. |
Q58582917 | Synaptic distributions of pS214-tau in rhesus monkey prefrontal cortex are associated with spine density, but not with cognitive decline |
Q35016901 | Targeting gonadotropins: an alternative option for Alzheimer disease treatment |
Q36475967 | Testosterone replacement therapy for late-onset hypogonadism |
Q58614226 | The Association Between Body Mass Index, and Cognitive, Functional, and Behavioral Declines for Incident Dementia |
Q33873941 | The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset |
Q21563448 | The Haunting of Medical Journals: How Ghostwriting Sold “HRT” |
Q35200989 | The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition |
Q38927944 | The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia. |
Q46797789 | The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline |
Q33275630 | The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial |
Q40190946 | The association between an inflammatory diet and global cognitive function and incident dementia in older women: The Women's Health Initiative Memory Study. |
Q30496612 | The cognitive effects of conjugated equine estrogens depend on whether menopause etiology is transitional or surgical |
Q36704008 | The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature? |
Q27693353 | The diagnosis and management of mild cognitive impairment: a clinical review |
Q37244686 | The differences in neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression |
Q45247132 | The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study |
Q37172024 | The effects of acute 17beta-estradiol treatment on gene expression in the young female mouse hippocampus. |
Q48130002 | The effects of chronic estradiol treatment on working memory deficits induced by combined infusion of beta-amyloid (1-42) and ibotenic acid |
Q37390076 | The expanding use of third-generation aromatase inhibitors: what the general internist needs to know |
Q33921182 | The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. |
Q28263673 | The potential for estrogens in preventing Alzheimer's disease and vascular dementia |
Q36933312 | The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). |
Q36304876 | The role of allelic variation in estrogen receptor genes and major depression in the Nurses Health Study |
Q37145381 | The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative |
Q38609082 | The role of menopausal hormone therapy in the management of osteoporosis |
Q61965640 | The timing of estrogen therapy after ovariectomy—implications for neurocognitive function |
Q34536301 | Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease |
Q34168826 | Thyroid Hormones Are Associated with Poorer Cognition in Mild Cognitive Impairment |
Q89308533 | Timing of cyclic estradiol treatment differentially affects cognition in aged female rhesus monkeys |
Q34683673 | Timing of hormone therapy and dementia: the critical window theory revisited |
Q34468841 | Tonic Premarin dose-dependently enhances memory, affects neurotrophin protein levels and alters gene expression in middle-aged rats. |
Q28600847 | Trajectories and phenotypes with estrogen exposures across the lifespan: What does Goldilocks have to do with it? |
Q34684381 | Translational research on the way to effective therapy for Alzheimer disease |
Q47148252 | Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders |
Q36213129 | Treatment of menopausal symptoms: what shall we do now? |
Q36784455 | Treatment of the mild cognitive impairment (MCI). |
Q35941842 | Update on the effect of estradiol in postmenopause women with Alzheimer's disease: a systematic review |
Q38106748 | Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. |
Q48671400 | Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health |
Q64055802 | Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study |
Q34038890 | Using genetics to enable studies on the prevention of Alzheimer's disease |
Q30513312 | Using predictors of hormone therapy use to model the healthy user bias: how does healthy user status influence cognitive effects of hormone therapy? |
Q34786018 | Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease |
Q28081565 | Utilizing induced pluripotent stem cells (iPSCs) to understand the actions of estrogens in human neurons |
Q34425445 | What is the best evidence for determining harms of medical treatment? |
Q53220661 | When practices, promises, profits, and policies outpace hard evidence: the post-menopausal hormone debate. |
Q36350786 | Where are we with postmenopausal hormone therapy in 2005? |
Q53282559 | [New therapeutic approaches in Alzheimer disease]. |
Q80252363 | [Preventing Alzheimer's disease: hopes and disappointments] |
Q83950697 | [Should we change our attitude on postmenopausal hormone replacement therapy?] |
Search more.